Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
IHH audit committee head opposed Fortis buy, says report

2h theedgemarkets
KUALA LUMPUR (July 23): An independent non-executive director of IHH Healthcare Bhd had voiced dissent over the group’s planned acquisition of a controlling stake in India’s Fortis Healthcare, according to India’s Economic Times.
5225 FORTIS FORTISMLR Q0F IHHHF 532843 523696

0
Pharma weekly wrap: Daiichi seeks stay on Fortis-IHH deal, Q1 results

13h moneycontrol
With the the approval of shareholders for IHH Healthcare's offer to buy Fortis now a mere formality, as the board’s choice may not face backlash from majority shareholders this time unlike previous occasions.
5225 FORTIS GLAXO GLXKY Q0F IHHHF 532843 500660

0
IHH open offer for Fortis stake to begin from Sep 7

2018-07-21 freepressjournal.in
New Delhi : IHH Healthcare’s open offer for 26 per cent stake in Fortis Healthcare will open on September 7 and close on September 24. This is the second step in its plan to acquire a controlling stake in the company.
5225 FORTIS Q0F IHHHF 532843

0
Fortis Healthcare Limited - Public Announcement-Open Offer

2018-07-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
FORTIS 532843

0
Fortis Healthcare Limited - News Clarification

2018-07-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
FORTIS 532843

1
IHH wins race to take over Fortis

2018-07-19 freepressjournal.in
New Delhi : Fortis Healthcare board on Friday approved Rs 4,000-crore offer from Malaysia’s IHH Healthcare for 31.1 per cent stake in it, valuing the cash-strapped firm at Rs 8,880 crore thus ending months of takeover battle.
5225 FORTIS FTS Q0F IHHHF 532843

0
Fortis stake sale to IHH faces roadblock

2018-07-19 freepressjournal.in
New Delhi : In a move that could delay its stake sale to IHH Healthcare, the Delhi High Court on Wednesday issued a notice to Fortis Healthcare on the proposed transaction and asked the company to file a reply within four weeks.
5225 FORTIS Q0F IHHHF 532843

0
Fortis EGM on Aug 13 to seek shareholders nod for stake sale to IHH

2018-07-19 moneycontrol
Fortis Healthcare today said extra ordinary general meeting (EGM) of the company will be held on August 13 to seek shareholders nod for its acquisition by Malaysia's IHH Healthcare. Last week, Fortis Healthcare board had approved a Rs 4,000-crore offer from IHH Healthcare for 31.1 percent stake in it, valuing the cash-strapped firm at Rs 8,880 crore.
5225 FORTIS Q0F IHHHF 532843

0
Fortis EGM on 13 August over stake sale to IHH

2018-07-19 livemint
New Delhi: Fortis Healthcare on Thursday said an extraordinary general meeting (EGM) of the company will be held on 13 August to seek shareholders’ nod for its acquisition by Malaysia’s IHH Healthcare.
5225 FORTIS Q0F IHHHF 532843

0
Fortis Healthcare Limited - Shareholders meeting

2018-07-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
FORTIS 532843

0
Fortis Healthcare Limited - News Clarification

2018-07-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
FORTIS 532843

0
Fortis stake sale to IHH faces roadblock

2018-07-19 freepressjournal.in
New Delhi : In a move that could delay its stake sale to IHH Healthcare, the Delhi High Court on Wednesday issued a notice to Fortis Healthcare on the proposed transaction and asked the company to file a reply within four weeks.
5225 FORTIS Q0F IHHHF 532843

0
Daiichi seeks stay on Fortis-IHH deal, cites Rs 3,500-cr arbitration case against Singh bros

2018-07-18 moneycontrol
Japanese drugmaker Daiichi Sankyo has sought a stay on the Fortis-IHH Healthcare deal, as it tries to enforce Rs 3,500-crore arbitration award against Fortis' erstwhile promoters, Malvinder Singh and Shivinder Singh.
FORTIS 532843

0
Fortis Healthcare Limited - Trading Window

2018-07-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
FORTIS 532843

0
IHH Healthcare seen on track for earnings recovery

2018-07-17 theedgemarkets
IHH Healthcare Bhd (July 16, RM6.01) Maintain buy with a target price (TP) of RM7.10: IHH’s proposed acquisition of a controlling stake in Fortis Healthcare (Fortis) is via a combination of i) proposed subscription of 235 million new Fortis shares (31% of total voting equity) through a preferential allotment and ii) mandatory open offer for Fortis and Fortis Malar, both of up to 26%. Cash consideration will range up to RM4.
5225 FORTIS Q0F IHHHF 532843

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...